KRYS (Krystal Biotech, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by KRYS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Julian S Gangolli | Director | A | — | — |
| 2026-09-16 | Everett Rand Sutherland | Director | A | — | — |
| 2026-09-16 | Christopher Mason | Director | A | — | — |
| 2026-09-16 | DANIEL JANNEY | Director | A | — | — |
| 2026-09-16 | Catherine Mazzacco | Director | A | — | — |
| 2026-09-16 | DINO A ROSSI | Director | A | — | — |
| 2026-09-04 | Suma Krishnan | President, R&D | Sell | — | — |
| 2026-09-04 | Krish S Krishnan | President and CEO | Sell | — | — |
| 2026-08-14 | DINO A ROSSI | Director | MIXED | — | — |
| 2026-06-26 | John Charles Thomas | EVP, General Counsel | MIXED | — | — |
| 2026-06-05 | Suma Krishnan | President, R&D | Sell | — | — |
| 2026-06-05 | Krish S Krishnan | President and CEO | Sell | — | — |
| 2026-05-27 | John Charles Thomas | EVP, General Counsel | Sell | — | — |
| 2026-03-06 | Suma Krishnan | President, R&D | Sell | — | — |
| 2026-03-06 | Krish S Krishnan | President and CEO | Sell | — | — |
| 2026-03-03 | DANIEL JANNEY | Director | Sell | — | — |
| 2026-03-03 | KATHRYN ROMANO | Chief Accounting Officer | MIXED | — | — |
| 2026-03-03 | Krish S Krishnan | President and CEO | MIXED | — | — |
| 2026-03-03 | Suma Krishnan | President, R&D | MIXED | — | — |
| 2026-02-26 | DANIEL JANNEY | Director | MIXED | — | — |
| 2026-02-23 | DINO A ROSSI | Director | MIXED | — | — |
| 2026-02-11 | KATHRYN ROMANO | Chief Accounting Officer | MIXED | — | — |
| 2025-12-05 | Suma Krishnan | President, R&D | MIXED | — | — |
| 2025-12-05 | Krish S Krishnan | President and CEO | MIXED | — | — |
| 2025-07-16 | Krish S Krishnan | President and CEO | Sell | — | — |
| 2025-07-16 | Suma Krishnan | President, R&D | Sell | — | — |
| 2025-07-11 | Suma Krishnan | President, R&D | Sell | — | — |
| 2025-07-11 | Krish S Krishnan | President and CEO | Sell | — | — |
| 2025-06-30 | DANIEL JANNEY | Director | A | — | — |
| 2025-06-30 | DINO A ROSSI | Director | A | — | — |
| 2025-06-30 | Everett Rand Sutherland | Director | A | — | — |
| 2025-06-30 | Catherine Mazzacco | Director | A | — | — |
| 2025-06-30 | Julian S Gangolli | Director | A | — | — |
| 2025-06-30 | Christopher Mason | Director | A | — | — |
| 2025-03-13 | Krish S Krishnan | President and CEO | Sell | — | — |
| 2025-03-13 | Suma Krishnan | President, R&D | Sell | — | — |
| 2025-02-28 | KATHRYN ROMANO | Chief Accounting Officer | MIXED | — | — |
| 2025-02-28 | Krish S Krishnan | President and CEO | MIXED | — | — |
| 2025-02-28 | Suma Krishnan | President, R&D | MIXED | — | — |
| 2024-12-13 | Krish S Krishnan | President and CEO | Sell | — | — |
| 2024-12-13 | Suma Krishnan | President, R&D | Sell | — | — |
| 2024-09-13 | DINO A ROSSI | Director | G | — | — |
| 2024-09-13 | Krish S Krishnan | President and CEO | Sell | — | — |
| 2024-09-13 | Suma Krishnan | President, R&D | Sell | — | — |
| 2024-07-01 | Julian S Gangolli | Director | A | — | — |
| 2024-07-01 | DANIEL JANNEY | Director | A | — | — |
| 2024-07-01 | Christopher Mason | Director | A | — | — |
| 2024-07-01 | Catherine Mazzacco | Director | A | — | — |
| 2024-07-01 | Everett Rand Sutherland | Director | A | — | — |
| 2024-07-01 | DINO A ROSSI | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 1,400,726 | — |
| — | President, R&D | 1,356,274 | — |
| — | Director | 74,036 | — |
| — | Director | 53,135 | — |
| — | Chief Accounting Officer | 23,356 | — |
| — | Chief Financial Officer | 9,050 | — |
| — | Director | 9,000 | — |
| — | EVP, General Counsel | 1,000 | — |
| — | Chief Commercial Officer | 433 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KRYS quote page; the site-wide leaderboard is on the insider transactions hub.